<DOC>
	<DOCNO>NCT01087944</DOCNO>
	<brief_summary>This randomize , cross-over , open label study compare tolerability handle application peginterferon alfa-2a [ Pegasys ] autoinjector versus pre-filled syringe patient chronic hepatitis C , either treatment peginterferon alfa-2a least 12 week treatment-naïve peginterferon alfa-2a . Patients randomize self-injection 180mcg peginterferon alfa-2a week use either autoinjector prefilled syringe 3 week , switch use method injection another 3 week . Anticipated time study treatment 6 week . Target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Study Administration Peginterferon Alfa-2a Pegasys Autoinjector Versus Pre-filled Syringe Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; /=18 year age chronic hepatitis C treatment peginterferon alfa2a &gt; /= 12 week baseline , treatmentnaïve peginterferon alfa2a history evidence decompensated liver disease autoimmune hepatitis hypersensitivity peginterferon alfa2a component concomitant treatment require administration selfinjection , prior use autoinjector</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>